MindMaze Therapeutics

MindMaze operates across digital neurorehabilitation, medical devices, and therapeutics, combining software-led therapy with sensors, devices, and clinical monitoring. Its product range spans MindMotion PRO and MindMotion GO for game-based rehabilitation, MindPod Dolphin for immersive therapy, and devices such as Izar and Intento PRO. The company’s stated model extends care from hospitals and outpatient facilities to patients’ homes, with its Companion platform supporting clinician monitoring and treatment adjustments. This gives MindMaze a broader rehabilitation workflow than a single-purpose therapy app or device, while its clinical and channel relationship with Vibra Healthcare provides a route into U.S. inpatient rehabilitation settings. MindMaze is best characterized by its combination of rehabilitation hardware, immersive and game-based therapies, and remote-care capabilities.

MindMaze’s trajectory combines a long research-to-product development arc with a newer emphasis on commercialization and restructuring. Founded in 2012 in Lausanne, it built a portfolio spanning digital rehabilitation, motion tracking, immersive therapy, and neurostimulation. Earlier expansion included acquisitions of Gait Up in 2017 and Intento, NeuroPro, and Neuro Motor Innovations in 2018. The company raised $100 million in a 2016 Series A, followed by reported 2021 and 2022 venture rounds of $125 million and $105 million; the 2022 round is the latest round in the listed funding history. In 2026, the inflection points are more operational: Zach Henderson’s CEO appointment in March, expanded commercial ties with Vibra Healthcare, CHF 8 million in strategic equity financing in May, and a June non-core asset sale and organizational simplification. These steps suggest a focus on scaling selected neurotherapeutics and concentrating resources, rather than expansion through acquisitions.